Systematically Optimized Imiquimod-Loaded Novel Hybrid Vesicles by Employing Design of Experiment (DoE) Approach with Improved Biocompatibility, Stability, and Dermatokinetic Profile View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-05

AUTHORS

Mandeep Sharma, Gajanand Sharma, Bhupinder Singh, Om Prakash Katare

ABSTRACT

The present research work explored the possibility of harnessing the benefits of vesicular carriers for overcoming imiquimod-associated complaints or side effects. Hybrid vesicles were prepared by the most common and easily scalable method, i.e., thin film hydration. The chaffing of myriad of factors, both process and material related, affecting the desirable attributes of conceived vesicles, was performed through Taguchi design. Based upon the analysis of Pareto chart and prior experiences, concentration of phospholipid and poloxamer 407 was selected for optimization by 2 levels, 13 run central composite design (CCD). The optimized hybrid vesicles contained 1% w/v phospholipid and 3% w/v poloxamer 407. The optimized hybrid vesicles were incorporated into the 3% w/v carbopol 940 gel and characterized for morphology, physicochemical properties, and rheological behavior. The release (%) and skin retention (% of total dose) across rat skin from gel at same amount of formulation was more than Imiquad®. The gel delivered the loaded cargo, preferably, in the viable region of skin and formed local depot in confocal microscopic studies. The gel followed one compartment open body dermatokinetic model in rat skin. There was not any harmful effect on the mice skin after repeated applications. The gel was stable at room conditions for 1 year. More... »

PAGES

156

Journal

TITLE

AAPS PharmSciTech

ISSUE

4

VOLUME

20

Author Affiliations

Identifiers

URI

http://scigraph.springernature.com/pub.10.1208/s12249-019-1331-1

DOI

http://dx.doi.org/10.1208/s12249-019-1331-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113085847

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30927154


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0306", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Physical Chemistry (incl. Structural)", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Chemical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Panjab University", 
          "id": "https://www.grid.ac/institutes/grid.261674.0", 
          "name": [
            "University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, 160014, Chandigarh, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sharma", 
        "givenName": "Mandeep", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Panjab University", 
          "id": "https://www.grid.ac/institutes/grid.261674.0", 
          "name": [
            "University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, 160014, Chandigarh, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sharma", 
        "givenName": "Gajanand", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Panjab University", 
          "id": "https://www.grid.ac/institutes/grid.261674.0", 
          "name": [
            "University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, 160014, Chandigarh, India", 
            "UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites, Panjab University, 160 014, Chandigarh, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Singh", 
        "givenName": "Bhupinder", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Panjab University", 
          "id": "https://www.grid.ac/institutes/grid.261674.0", 
          "name": [
            "University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, 160014, Chandigarh, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Katare", 
        "givenName": "Om Prakash", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1477-3155-12-17", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001620111", 
          "https://doi.org/10.1186/1477-3155-12-17"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12249-016-0489-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004191963", 
          "https://doi.org/10.1208/s12249-016-0489-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/08982104.2014.907305", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005822084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-31187-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006335213", 
          "https://doi.org/10.1007/978-3-642-31187-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-31187-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006335213", 
          "https://doi.org/10.1007/978-3-642-31187-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncomms2566", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007297261", 
          "https://doi.org/10.1038/ncomms2566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.chemphyslip.2016.10.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007330938"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200767150-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015538611", 
          "https://doi.org/10.2165/00003495-200767150-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1473-2165.2009.00468.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016974523"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1473-2165.2009.00468.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016974523"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2005.10.023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021437370"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/21691401.2014.953633", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025842346"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4103/0250-474x.25707", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030195734"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10856-015-5524-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050883183", 
          "https://doi.org/10.1007/s10856-015-5524-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bmcl.2007.06.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052735643"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/08982104.2012.700459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053656287"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/mp300722f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056213198"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1615/critrevtherdrugcarriersyst.v22.i1.20", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068133314"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/187221312798889301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069224882"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078629484", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/08982104.2017.1295989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083925777"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/1389200218666170306104042", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084390693"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3390/pharmaceutics9020012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084436901"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.15171/apb.2017.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085252531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.15171/apb.2017.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090932837"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12249-018-0962-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101183216", 
          "https://doi.org/10.1208/s12249-018-0962-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12249-018-0962-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101183216", 
          "https://doi.org/10.1208/s12249-018-0962-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12249-018-0962-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101183216", 
          "https://doi.org/10.1208/s12249-018-0962-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-05", 
    "datePublishedReg": "2019-05-01", 
    "description": "The present research work explored the possibility of harnessing the benefits of vesicular carriers for overcoming imiquimod-associated complaints or side effects. Hybrid vesicles were prepared by the most common and easily scalable method, i.e., thin film hydration. The chaffing of myriad of factors, both process and material related, affecting the desirable attributes of conceived vesicles, was performed through Taguchi design. Based upon the analysis of Pareto chart and prior experiences, concentration of phospholipid and poloxamer 407 was selected for optimization by 2 levels, 13 run central composite design (CCD). The optimized hybrid vesicles contained 1% w/v phospholipid and 3% w/v poloxamer 407. The optimized hybrid vesicles were incorporated into the 3% w/v carbopol 940 gel and characterized for morphology, physicochemical properties, and rheological behavior. The release (%) and skin retention (% of total dose) across rat skin from gel at same amount of formulation was more than Imiquad\u00ae. The gel delivered the loaded cargo, preferably, in the viable region of skin and formed local depot in confocal microscopic studies. The gel followed one compartment open body dermatokinetic model in rat skin. There was not any harmful effect on the mice skin after repeated applications. The gel was stable at room conditions for 1\u00a0year.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1208/s12249-019-1331-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1023420", 
        "issn": [
          "1530-9932"
        ], 
        "name": "AAPS PharmSciTech", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "name": "Systematically Optimized Imiquimod-Loaded Novel Hybrid Vesicles by Employing Design of Experiment (DoE) Approach with Improved Biocompatibility, Stability, and Dermatokinetic Profile", 
    "pagination": "156", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1839251c3cb4cd7b891a7a208dac349338f83be815aeefdc02c6f286359cdb41"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30927154"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100960111"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1208/s12249-019-1331-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113085847"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1208/s12249-019-1331-1", 
      "https://app.dimensions.ai/details/publication/pub.1113085847"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000369_0000000369/records_68956_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1208%2Fs12249-019-1331-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1208/s12249-019-1331-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1208/s12249-019-1331-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1208/s12249-019-1331-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1208/s12249-019-1331-1'


 

This table displays all metadata directly associated to this object as RDF triples.

164 TRIPLES      21 PREDICATES      53 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1208/s12249-019-1331-1 schema:about anzsrc-for:03
2 anzsrc-for:0306
3 schema:author N8aea45f7d9464fa68afa1f5ff2dad49a
4 schema:citation sg:pub.10.1007/978-3-642-31187-1
5 sg:pub.10.1007/s10856-015-5524-1
6 sg:pub.10.1038/ncomms2566
7 sg:pub.10.1186/1477-3155-12-17
8 sg:pub.10.1208/s12249-016-0489-z
9 sg:pub.10.1208/s12249-018-0962-y
10 sg:pub.10.2165/00003495-200767150-00006
11 https://app.dimensions.ai/details/publication/pub.1078629484
12 https://doi.org/10.1016/j.bmcl.2007.06.020
13 https://doi.org/10.1016/j.chemphyslip.2016.10.005
14 https://doi.org/10.1016/j.ijpharm.2005.10.023
15 https://doi.org/10.1021/mp300722f
16 https://doi.org/10.1080/08982104.2017.1295989
17 https://doi.org/10.1111/j.1473-2165.2009.00468.x
18 https://doi.org/10.15171/apb.2017.002
19 https://doi.org/10.15171/apb.2017.028
20 https://doi.org/10.1615/critrevtherdrugcarriersyst.v22.i1.20
21 https://doi.org/10.2174/1389200218666170306104042
22 https://doi.org/10.2174/187221312798889301
23 https://doi.org/10.3109/08982104.2012.700459
24 https://doi.org/10.3109/08982104.2014.907305
25 https://doi.org/10.3109/21691401.2014.953633
26 https://doi.org/10.3390/pharmaceutics9020012
27 https://doi.org/10.4103/0250-474x.25707
28 schema:datePublished 2019-05
29 schema:datePublishedReg 2019-05-01
30 schema:description The present research work explored the possibility of harnessing the benefits of vesicular carriers for overcoming imiquimod-associated complaints or side effects. Hybrid vesicles were prepared by the most common and easily scalable method, i.e., thin film hydration. The chaffing of myriad of factors, both process and material related, affecting the desirable attributes of conceived vesicles, was performed through Taguchi design. Based upon the analysis of Pareto chart and prior experiences, concentration of phospholipid and poloxamer 407 was selected for optimization by 2 levels, 13 run central composite design (CCD). The optimized hybrid vesicles contained 1% w/v phospholipid and 3% w/v poloxamer 407. The optimized hybrid vesicles were incorporated into the 3% w/v carbopol 940 gel and characterized for morphology, physicochemical properties, and rheological behavior. The release (%) and skin retention (% of total dose) across rat skin from gel at same amount of formulation was more than Imiquad®. The gel delivered the loaded cargo, preferably, in the viable region of skin and formed local depot in confocal microscopic studies. The gel followed one compartment open body dermatokinetic model in rat skin. There was not any harmful effect on the mice skin after repeated applications. The gel was stable at room conditions for 1 year.
31 schema:genre research_article
32 schema:inLanguage en
33 schema:isAccessibleForFree false
34 schema:isPartOf N6c91b74fbd414f53887599a1839b2a3b
35 Naf996b986c2745198dcdadd72d20bb93
36 sg:journal.1023420
37 schema:name Systematically Optimized Imiquimod-Loaded Novel Hybrid Vesicles by Employing Design of Experiment (DoE) Approach with Improved Biocompatibility, Stability, and Dermatokinetic Profile
38 schema:pagination 156
39 schema:productId N10549bb60a1b4278bff153f29d95ffe9
40 N18e5af1d08284634b7170dafcab3a005
41 N211785787e0a4624bb4bc81d84ef48ac
42 N4176ab7f1e9440d08ce10277107c771b
43 N9955ca3e3d5644ef9abd2c7f1dafccc0
44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113085847
45 https://doi.org/10.1208/s12249-019-1331-1
46 schema:sdDatePublished 2019-04-11T13:23
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher Nab4e4c19cba040968286e50551764812
49 schema:url https://link.springer.com/10.1208%2Fs12249-019-1331-1
50 sgo:license sg:explorer/license/
51 sgo:sdDataset articles
52 rdf:type schema:ScholarlyArticle
53 N067e589dcc5d47c8bed7678509ff07ec rdf:first Nc9660d63db624be486e37e69598e3003
54 rdf:rest N236293d978a948d99a96acdd598cfef7
55 N08ee5d519f7f4ec3bd88433c3c4b3e30 schema:affiliation https://www.grid.ac/institutes/grid.261674.0
56 schema:familyName Katare
57 schema:givenName Om Prakash
58 rdf:type schema:Person
59 N10549bb60a1b4278bff153f29d95ffe9 schema:name doi
60 schema:value 10.1208/s12249-019-1331-1
61 rdf:type schema:PropertyValue
62 N18e5af1d08284634b7170dafcab3a005 schema:name nlm_unique_id
63 schema:value 100960111
64 rdf:type schema:PropertyValue
65 N211785787e0a4624bb4bc81d84ef48ac schema:name readcube_id
66 schema:value 1839251c3cb4cd7b891a7a208dac349338f83be815aeefdc02c6f286359cdb41
67 rdf:type schema:PropertyValue
68 N236293d978a948d99a96acdd598cfef7 rdf:first N08ee5d519f7f4ec3bd88433c3c4b3e30
69 rdf:rest rdf:nil
70 N2ebe4d7f71324e9c89dc03fa01059027 schema:affiliation https://www.grid.ac/institutes/grid.261674.0
71 schema:familyName Sharma
72 schema:givenName Gajanand
73 rdf:type schema:Person
74 N3fdfbcf492e4402da4d2b9e5384ed312 rdf:first N2ebe4d7f71324e9c89dc03fa01059027
75 rdf:rest N067e589dcc5d47c8bed7678509ff07ec
76 N4176ab7f1e9440d08ce10277107c771b schema:name pubmed_id
77 schema:value 30927154
78 rdf:type schema:PropertyValue
79 N6c91b74fbd414f53887599a1839b2a3b schema:volumeNumber 20
80 rdf:type schema:PublicationVolume
81 N8aea45f7d9464fa68afa1f5ff2dad49a rdf:first Na4e8165057534fc7bd9efd63770ae76c
82 rdf:rest N3fdfbcf492e4402da4d2b9e5384ed312
83 N9955ca3e3d5644ef9abd2c7f1dafccc0 schema:name dimensions_id
84 schema:value pub.1113085847
85 rdf:type schema:PropertyValue
86 Na4e8165057534fc7bd9efd63770ae76c schema:affiliation https://www.grid.ac/institutes/grid.261674.0
87 schema:familyName Sharma
88 schema:givenName Mandeep
89 rdf:type schema:Person
90 Nab4e4c19cba040968286e50551764812 schema:name Springer Nature - SN SciGraph project
91 rdf:type schema:Organization
92 Naf996b986c2745198dcdadd72d20bb93 schema:issueNumber 4
93 rdf:type schema:PublicationIssue
94 Nc9660d63db624be486e37e69598e3003 schema:affiliation https://www.grid.ac/institutes/grid.261674.0
95 schema:familyName Singh
96 schema:givenName Bhupinder
97 rdf:type schema:Person
98 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
99 schema:name Chemical Sciences
100 rdf:type schema:DefinedTerm
101 anzsrc-for:0306 schema:inDefinedTermSet anzsrc-for:
102 schema:name Physical Chemistry (incl. Structural)
103 rdf:type schema:DefinedTerm
104 sg:journal.1023420 schema:issn 1530-9932
105 schema:name AAPS PharmSciTech
106 rdf:type schema:Periodical
107 sg:pub.10.1007/978-3-642-31187-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006335213
108 https://doi.org/10.1007/978-3-642-31187-1
109 rdf:type schema:CreativeWork
110 sg:pub.10.1007/s10856-015-5524-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050883183
111 https://doi.org/10.1007/s10856-015-5524-1
112 rdf:type schema:CreativeWork
113 sg:pub.10.1038/ncomms2566 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007297261
114 https://doi.org/10.1038/ncomms2566
115 rdf:type schema:CreativeWork
116 sg:pub.10.1186/1477-3155-12-17 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001620111
117 https://doi.org/10.1186/1477-3155-12-17
118 rdf:type schema:CreativeWork
119 sg:pub.10.1208/s12249-016-0489-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1004191963
120 https://doi.org/10.1208/s12249-016-0489-z
121 rdf:type schema:CreativeWork
122 sg:pub.10.1208/s12249-018-0962-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1101183216
123 https://doi.org/10.1208/s12249-018-0962-y
124 rdf:type schema:CreativeWork
125 sg:pub.10.2165/00003495-200767150-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015538611
126 https://doi.org/10.2165/00003495-200767150-00006
127 rdf:type schema:CreativeWork
128 https://app.dimensions.ai/details/publication/pub.1078629484 schema:CreativeWork
129 https://doi.org/10.1016/j.bmcl.2007.06.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052735643
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1016/j.chemphyslip.2016.10.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007330938
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1016/j.ijpharm.2005.10.023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021437370
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1021/mp300722f schema:sameAs https://app.dimensions.ai/details/publication/pub.1056213198
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1080/08982104.2017.1295989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083925777
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1111/j.1473-2165.2009.00468.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1016974523
140 rdf:type schema:CreativeWork
141 https://doi.org/10.15171/apb.2017.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085252531
142 rdf:type schema:CreativeWork
143 https://doi.org/10.15171/apb.2017.028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090932837
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1615/critrevtherdrugcarriersyst.v22.i1.20 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068133314
146 rdf:type schema:CreativeWork
147 https://doi.org/10.2174/1389200218666170306104042 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084390693
148 rdf:type schema:CreativeWork
149 https://doi.org/10.2174/187221312798889301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069224882
150 rdf:type schema:CreativeWork
151 https://doi.org/10.3109/08982104.2012.700459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053656287
152 rdf:type schema:CreativeWork
153 https://doi.org/10.3109/08982104.2014.907305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005822084
154 rdf:type schema:CreativeWork
155 https://doi.org/10.3109/21691401.2014.953633 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025842346
156 rdf:type schema:CreativeWork
157 https://doi.org/10.3390/pharmaceutics9020012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084436901
158 rdf:type schema:CreativeWork
159 https://doi.org/10.4103/0250-474x.25707 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030195734
160 rdf:type schema:CreativeWork
161 https://www.grid.ac/institutes/grid.261674.0 schema:alternateName Panjab University
162 schema:name UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites, Panjab University, 160 014, Chandigarh, India
163 University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, 160014, Chandigarh, India
164 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...